Shree Ganesh Bio

Why is Shree Ganesh Biotech India Ltd falling/rising?

As of 03-Aug, Shree Ganesh Biotech India Ltd's stock is at 0.54, down 1.82%, significantly underperforming the Sensex. The stock has seen a steep decline over various time frames, indicating operational challenges and a lack of investor confidence.

As of 03-Aug, Shree Ganesh Biotech India Ltd's stock price is falling, currently at 0.54, which reflects a change of -0.01 or -1.82%. The stock has underperformed significantly compared to the benchmark Sensex, which has gained 2.35% over the past week while Shree Ganesh Biotech has declined by the same percentage. Over the past month, the stock has decreased by 3.57%, while the Sensex has increased by 1.13%. <BR><BR>Year-to-date, the stock has fallen by 12.90%, compared to a 7.72% decline in the Sensex. Over the past year, the stock has experienced a substantial drop of 31.65%, whereas the Sensex has only decreased by 2.43%. The long-term performance is even more concerning, with a 47.06% decline over three years and a staggering 91.50% drop over five years, while the Sensex has risen by 20.54% and 46.11% respectively during those periods.<BR><BR>Today's performance indicates that the stock is close to its 52-week low, being only 3.7% away from a low of Rs 0.52. The stock has been losing for the last two days, with a total decline of 3.57% in that period. Additionally, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend.<BR><BR>Investor participation is also declining, as evidenced by a drop in delivery volume by 0.95% against the 5-day average. The company is facing significant operational challenges, including operating losses and a weak ability to service its debt, indicated by a poor EBIT to Interest ratio of 0.65. Furthermore, the company has recorded a negative EBITDA of Rs. -0.96 crore, which adds to the risk associated with the stock. Given these factors, the stock's performance reflects a lack of investor confidence and a challenging financial outlook, contributing to its current decline.

Which are the latest news on Shree Ganesh Bio?

Should I buy, sell or hold Shree Ganesh Biotech India Ltd?

When is the next results date for Shree Ganesh Biotech India Ltd?

The next results date for Shree Ganesh Biotech India Ltd is August 4, 2026.

The next results date for Shree Ganesh Biotech India Ltd is scheduled for August 4, 2026.

What does Shree Ganesh Bio do?

Shree Ganesh Biotech India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1982. As of March 2026, it reported net sales of 2 Cr and a market cap of INR 24 Cr, with a P/E ratio of 47.00.

Overview:<BR>Shree Ganesh Biotech India Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on September 2, 1982, originally as 'S.P. Commercial Co. Limited'. It received its Certificate of Commencement of Business on September 14, 1982. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 47.00<BR>- Industry P/E: 36<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.12<BR>- Return on Equity: 0.80%<BR>- Price to Book: 0.38<BR><BR>Contact Details:<BR>Address: 6 Flr Premises-602 Mahavir Apt, 2 Aushutosh Mukherjee Road Kolkata West Bengal : 700020<BR>Email: shreeganeshbiotechindialtd@gmail.co<BR>Website: http://shreeganeshbiotech.tech/

How big is Shree Ganesh Bio?

As of 10th June, Shree Ganesh Biotech India Ltd has a market capitalization of 24.00 Cr, with recent net sales of 4.97 Cr and a net profit of 0.51 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Shree Ganesh Biotech India Ltd has a market capitalization of 24.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4.97 Cr, while the sum of Net Profit for the same period is 0.51 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 63.26 Cr, and Total Assets amount to 63.49 Cr.

Who are in the management team of Shree Ganesh Bio?

The management team of Shree Ganesh Bio includes Aman Patel (Chairman & Wholetime Director), Kishan Nityanand Naidu, Harshad Rathod, Amrutaben Solanki (all Directors), and independent directors Sombir Singh, Chandni Solanki, Nimeshkumar Parmar, along with Namita Acharya as Company Secretary & Compliance Officer. They are responsible for overseeing the company's operations and governance.

The management team of Shree Ganesh Bio includes the following individuals:<BR><BR>1. Aman Patel - Chairman & Wholetime Director<BR>2. Kishan Nityanand Naidu - Director<BR>3. Harshad Rathod - Director<BR>4. Amrutaben Solanki - Director<BR>5. Sombir Singh - Independent Director<BR>6. Chandni Solanki - Independent Director<BR>7. Nimeshkumar Parmar - Independent Director<BR>8. Namita Acharya - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in overseeing the company's operations and governance.

Who are the peers of the Shree Ganesh Bio?

Shree Ganesh Bio's peers include Chandra Bhagat, Medi Caps, Welcure Drugs, and others, with varying management and growth risks. Centuple Global leads in 1-year returns at 105.84%, while Shree Ganesh Bio's return is -33.71%.

Peers: The peers of Shree Ganesh Bio are Chandra Bhagat, Medi Caps, Welcure Drugs, Guj. Terce Labs., Ishita Drugs, Venmax Drugs, Centuple Global, Cian Healthcare, Medicamen Organ, and Mono Pharmacare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Chandra Bhagat, Medi Caps, Welcure Drugs, Guj. Terce Labs., Ishita Drugs, Venmax Drugs, Cian Healthcare, Medicamen Organ, and Mono Pharmacare, while Average management risk is found at Welcure Drugs. Good growth is noted at Medi Caps, Welcure Drugs, Ishita Drugs, and Centuple Global, while Below Average growth is seen at Chandra Bhagat, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Medicamen Organ, and Mono Pharmacare. Shree Ganesh Bio has a Good capital structure, while Below Average capital structure is present at Chandra Bhagat, Guj. Terce Labs., Venmax Drugs, Cian Healthcare, Medicamen Organ, and Mono Pharmacare.<BR><BR>Return Snapshot: Centuple Global has the highest 1-year return at 105.84%, while Medi Caps has the lowest at -37.73%. Shree Ganesh Bio's 1-year return of -33.71% is better than Medi Caps but worse than Centuple Global. Additionally, the six-month return is negative for Welcure Drugs, Venmax Drugs, Centuple Global, and Medicamen Organ.

Are Shree Ganesh Biotech India Ltd latest results good or bad?

Shree Ganesh Biotech India Ltd's latest results are concerning, showing a net profit loss of ₹0.15 crores and a negative operating margin of -20.28%, despite a 202.86% increase in revenue quarter-over-quarter. Overall, the company's financial health appears weak, with ongoing challenges in profitability and negative returns for shareholders.

The latest results for Shree Ganesh Biotech India Ltd are concerning. In the fourth quarter of FY26, the company reported a net profit loss of ₹0.15 crores, which is a significant decline of 146.88% compared to the previous quarter's profit of ₹0.32 crores. This indicates a troubling trend in profitability.<BR><BR>On the revenue front, there was a substantial sequential increase of 202.86%, bringing the total revenue to ₹2.12 crores. However, this figure represents a year-on-year decline of 29.57%, highlighting ongoing challenges in sustaining revenue growth.<BR><BR>The operating margin was deeply negative at -20.28%, reflecting significant operational difficulties. The return on equity (ROE) was also negative at -0.46%, suggesting that the company is not generating value for its shareholders.<BR><BR>Overall, while there was a notable increase in revenue quarter-over-quarter, the persistent losses and negative margins indicate serious operational issues. Investors may find these results troubling, and the company's overall financial health appears to be weak.

How has been the historical performance of Shree Ganesh Bio?

Shree Ganesh Bio has experienced a significant decline in financial performance, with net sales dropping from 62.45 Cr in March 2023 to 22.96 Cr by March 2025, and profit after tax decreasing from 2.53 Cr to 0.28 Cr during the same period. Additionally, cash flow from operating activities turned negative in March 2025, indicating operational challenges.

Answer:<BR>The historical performance of Shree Ganesh Bio shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Shree Ganesh Bio's net sales peaked in March 2023 at 62.45 Cr, but have since declined to 22.96 Cr by March 2025. The total operating income followed a similar trend, decreasing from 72.64 Cr in March 2022 to 22.96 Cr in March 2025. Raw material costs have also decreased, from 68.84 Cr in March 2022 to 22.64 Cr in March 2025. The company reported an operating profit (PBDIT) of 0.39 Cr in March 2025, down from 3.49 Cr in March 2022, indicating a decline in profitability. Profit after tax has also decreased significantly from 2.53 Cr in March 2022 to 0.28 Cr in March 2025. The total liabilities have decreased from 93.55 Cr in March 2022 to 63.49 Cr in March 2025, while total assets have similarly declined from 93.55 Cr to 63.49 Cr over the same period. The cash flow from operating activities turned negative in March 2025 at -10.00 Cr, contrasting with positive cash flows in previous years. Overall, the financial performance of Shree Ganesh Bio has shown a downward trend in sales, profits, and cash flow, reflecting challenges in its operational efficiency and market conditions.

Who are the top shareholders of the Shree Ganesh Bio?

The top shareholders of Shree Ganesh Bio are primarily individual investors, holding 95.24% of the shares, while one Foreign Institutional Investor and New Era Fund Limited each hold 1.42%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Shree Ganesh Bio include a significant portion of individual investors, who hold 95.24% of the shares. Among institutional investors, there is one Foreign Institutional Investor (FII) that holds 1.42% of the shares. The highest public shareholder is New Era Fund Limited, which also holds 1.42%. Notably, there are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Is Shree Ganesh Bio overvalued or undervalued?

As of February 14, 2024, Shree Ganesh Bio is considered overvalued and risky, with a PE Ratio of 35.48, negative EV to EBIT, and a PEG Ratio of 0.00, reflecting operational challenges and a significant underperformance of -23.93% over the past year compared to a 7.61% gain in the Sensex.

As of 14 February 2024, the valuation grade for Shree Ganesh Bio has moved from expensive to risky, indicating a significant shift in perception regarding its financial health. The company is currently assessed as overvalued. Key ratios reflect this concern, with a PE Ratio of 35.48, an EV to EBIT of -33.78, and a Price to Book Value of 0.56, suggesting that the stock price is not justified by its earnings or asset value.<BR><BR>In comparison to peers, Shree Ganesh Bio's PE ratio stands out against industry benchmarks, while its negative EV to EBIT and EV to EBITDA ratios highlight operational challenges. Notably, the company has a PEG Ratio of 0.00, indicating no growth expectations, which further supports the overvaluation assessment. Over the past year, Shree Ganesh Bio has underperformed significantly, with a stock return of -23.93% compared to a 7.61% gain in the Sensex, reinforcing the notion that the stock may not be a sound investment at its current price.

What is the technical trend for Shree Ganesh Bio?

As of March 21, 2025, Shree Ganesh Bio's technical trend has shifted to a bearish stance with weak strength, indicated by bearish MACD, RSI, moving averages, and KST across multiple timeframes, while Bollinger Bands suggest a mildly bearish trend.

As of 21 March 2025, the technical trend for Shree Ganesh Bio has changed from mildly bearish to bearish. The current stance is bearish with a weak strength. Key indicators driving this include a bearish MACD on the weekly chart, a bearish RSI on the weekly chart, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on both the weekly and monthly charts, while Bollinger Bands indicate a mildly bearish trend on both weekly and monthly timeframes. The Dow Theory shows no trend on both weekly and monthly levels, further supporting the bearish outlook.

What is the bonus history of the Shree Ganesh Bio?

Shree Ganesh Bio issued a 1:1 bonus on April 27, 2022, with a record date of April 28, 2022, granting shareholders one additional share for each share owned.

Shree Ganesh Bio has a recent bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of April 27, 2022, and the record date was April 28, 2022. This means that shareholders received one additional share for every share they owned as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Shree Ganesh Bio declared dividend?

No Dividend History Available